MML Investors Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.51M | Buy |
12,020
+1,090
| +10% | +$137K | ﹤0.01% | 1423 |
|
|
2025
Q1 | $1.21M | Sell |
10,930
-462
| -4% | -$51.1K | ﹤0.01% | 1460 |
|
|
2024
Q4 | $1.56M | Buy |
11,392
+1,559
| +16% | +$213K | 0.01% | 1258 |
|
|
2024
Q3 | $1.13M | Sell |
9,833
-129
| -1% | -$14.9K | ﹤0.01% | 1394 |
|
|
2024
Q2 | $1.37M | Sell |
9,962
-74
| -0.7% | -$10.2K | 0.01% | 1233 |
|
|
2024
Q1 | $1.38M | Buy |
10,036
+2,756
| +38% | +$380K | 0.01% | 1240 |
|
|
2023
Q4 | $959K | Buy |
7,280
+1,215
| +20% | +$160K | ﹤0.01% | 1396 |
|
|
2023
Q3 | $682K | Buy |
6,065
+107
| +2% | +$12K | ﹤0.01% | 1453 |
|
|
2023
Q2 | $562K | Sell |
5,958
-954
| -14% | -$90K | ﹤0.01% | 1566 |
|
|
2023
Q1 | $700K | Sell |
6,912
-1,392
| -17% | -$141K | ﹤0.01% | 1242 |
|
|
2022
Q4 | $992K | Buy |
8,304
+1,212
| +17% | +$145K | 0.01% | 1153 |
|
|
2022
Q3 | $753K | Buy |
7,092
+123
| +2% | +$13.1K | 0.01% | 1211 |
|
|
2022
Q2 | $679K | Buy |
6,969
+319
| +5% | +$31.1K | 0.01% | 1248 |
|
|
2022
Q1 | $623K | Buy |
6,650
+1,944
| +41% | +$182K | ﹤0.01% | 1339 |
|
|
2021
Q4 | $401K | Sell |
4,706
-3,752
| -44% | -$320K | ﹤0.01% | 1534 |
|
|
2021
Q3 | $811K | Sell |
8,458
-136
| -2% | -$13K | 0.01% | 1117 |
|
|
2021
Q2 | $836K | Buy |
8,594
+1,918
| +29% | +$187K | 0.01% | 1077 |
|
|
2021
Q1 | $649K | Buy |
6,676
+205
| +3% | +$19.9K | 0.01% | 1131 |
|
|
2020
Q4 | $620K | Sell |
6,471
-1,578
| -20% | -$151K | 0.01% | 1049 |
|
|
2020
Q3 | $774K | Buy |
8,049
+4,873
| +153% | +$469K | 0.01% | 869 |
|
|
2020
Q2 | $387K | Buy |
+3,176
| New | +$387K | 0.01% | 1116 |
|
|
2020
Q1 | – | Sell |
-1,953
| Closed | -$210K | – | 1496 |
|
|
2019
Q4 | $210K | Buy |
+1,953
| New | +$210K | ﹤0.01% | 1411 |
|